Kim R. Tsuchimoto is Director at Monopar Therapeutics (MNPR). They have made 2 open-market trades across 1 company since 2012, most recently 2026-08-26.
CIK 0001333516
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3K since 2019, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MNPR | SELL · 10b5-1 | 2026-08-26 | 2026-08-27 | $111.39 | $456K | +1.6% | -25.2% | — |
| MNPR | SELL | 2025-07-14 | 2025-07-16 | $40.00 | $356K | +6.4% | -12.5% | +133.6% |
| MNPR | BUY | 2019-12-18 | 2019-12-20 | $8.00 | $3K | -31.5% | -31.7% | -73.0% |
| RPTP | SELL · 10b5-1 | 2012-08-29 | 2012-08-31 | $5.00 | $18K | N/A | N/A | N/A |
| RPTP | SELL · 10b5-1 | 2012-08-27 | 2012-08-29 | $5.00 | $245 | N/A | N/A | N/A |
| RPTP | SELL · 10b5-1 | 2012-06-15 | 2012-06-18 | $5.77 | $21K | N/A | N/A | N/A |
| RPTP | SELL · 10b5-1 | 2012-04-16 | 2012-04-17 | $6.05 | $22K | N/A | N/A | N/A |
| RPTP | SELL · 10b5-1 | 2012-02-15 | 2012-02-16 | $7.74 | $28K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.